0
Letters |

Iron Reduction and Cardiovascular OutcomesIron Reduction and Cardiovascular Outcomes

JAMA. 2007;297(19):2075-2076. doi:10.1001/jama.297.19.2075-a
Text Size: A A A
Published online

AUTHOR INFORMATION

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

IRON REDUCTION AND CARDIOVASCULAR OUTCOMES

To the Editor: The iron-heart hypothesis postulated a primary protective effect of iron depletion against ischemic heart disease.1 The report of the Iron (Fe) and Atherosclerosis Study (FeAST) by Dr Zacharski and colleagues2 had 2 key limitations as a general test of the idea: it was a trial of secondary prevention, and the iron-reduction protocol fell short of achieving full iron depletion.

Exploratory post hoc analyses suggested that reducing iron stores may improve outcomes for people with symptomatic but stable peripheral arterial disease if iron reduction is begun before age 60 years (unadjusted hazard ratio for the primary outcome, 0.47; 95% confidence interval, 0.24-0.90). The study findings would support a trial designed to test the original hypothesis using full iron depletion (defined as the absence of storage iron without significant iron-deficiency anemia), particularly among patients in this subgroup.

Zheng et al3 reported that frequent volunteer blood donors with a median serum ferritin value of 17 ng/mL had significantly better endothelial function than casual donors with a median value of 52 ng/mL. The participants in FeAST who were randomized to undergo iron reduction experienced a decrease in mean serum ferritin value from 122.5 ng/mL to 79.7 ng/mL.2 This suggests that improved outcomes could be associated with reductions of storage iron beyond those achieved in FeAST.

Before FeAST, ethical concerns put much greater weight on the risks of iron removal than on potential benefits.4 Limited iron reduction in FeAST reflected concern over the safety of iron removal in patients with peripheral arterial disease.5 Phlebotomy was apparently safe for participants randomized to undergo iron reduction, with the only adverse events associated with the 3141 reported phlebotomy episodes being 6 cases of “minor vasovagal events.” Lack of statistically significant cardiovascular benefit in older FeAST participants may have been attributable to the small amount of stored iron removed.2 In future trial designs, consideration should be given to the risk of failing to detect a large benefit because of inadequate treatment.

Financial Disclosures: None reported.

References
Sullivan JL. Iron and the sex difference in heart disease risk.  Lancet. 1981;11293-1294
PubMed
Zacharski LR, Chow BK, Howes PS.  et al.  Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial.  JAMA. 2007;297603-610
PubMed
Zheng H, Cable R, Spencer B, Votto N, Katz SD. Iron stores and vascular function in voluntary blood donors.  Arterioscler Thromb Vasc Biol. 2005;251577-1583
PubMed
Sullivan JL. Is stored iron safe?  J Lab Clin Med. 2004;144280-284
PubMed
Zacharski LR, Chow B, Lavori PW.  et al.  The Iron (Fe) and Atherosclerosis Study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease.  Am Heart J. 2000;139337-345
PubMed

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Sullivan JL. Iron and the sex difference in heart disease risk.  Lancet. 1981;11293-1294
PubMed
Zacharski LR, Chow BK, Howes PS.  et al.  Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial.  JAMA. 2007;297603-610
PubMed
Zheng H, Cable R, Spencer B, Votto N, Katz SD. Iron stores and vascular function in voluntary blood donors.  Arterioscler Thromb Vasc Biol. 2005;251577-1583
PubMed
Sullivan JL. Is stored iron safe?  J Lab Clin Med. 2004;144280-284
PubMed
Zacharski LR, Chow B, Lavori PW.  et al.  The Iron (Fe) and Atherosclerosis Study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease.  Am Heart J. 2000;139337-345
PubMed
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.